AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
St. Gallen, Switzerland, 13 December 2021 – Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions.
Vifor Pharma nimmt Stellung zu Medienspekulationen
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
St. Gallen, Switzerland, 13 December 2021 - Vifor führt mit CSL Gespräche über eine mögliche Transaktion. Entsprechende Entscheide sind noch nicht gefallen, es gibt diesbezüglich auch keine zeitlichen Vorgaben. Bis dahin kommentiert Vifor diese Gespräche nicht.
|
Contact and further information: |
||
|
Media Relations |
Investor Relations |
|
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
